Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tonix Pharmaceuticals has announced positive data from an animal pharmacokinetic (PK) study of sublingual (SL) formulation of TNX-102, the company's very low dose cyclobenzaprine.
Subscribe to our email newsletter
The SL TNX-102 (2.4mg) tablet was demonstrated to provide faster delivery and efficient absorption of cyclobenzaprine as compared to the currently available pills that deliver cyclobenzaprine to the stomach.
Tonix chief executive officer Seth Lederman said the company is developing TNX-102 as a therapy to help people afflicted with fibromyalgia (FM) get the relief they need, by improving sleep quality.
"The clinical data support the idea that improving sleep quality leads to significant alleviation of FM symptoms," Lederman added.
"We believe that improving sleep quality allows the natural restorative properties of sleep to work on reducing pain. TONIX is pursuing this goal through our novel formulations of cyclobenzaprine."
The company also plans to explore the utility of proprietary, low dose formulations of cyclobenzaprine in a new treatment paradigm for post-traumatic stress disorder.